Since winning FDA approval in fourth-line use to treat multiple myeloma in November 2015, Darzalex (daratumumab) has won approval in the EU and elsewhere, and seen a series of label expansions establishing it as an important single-agent therapy as well as in combination with other treatments. In 2017, worldwide sales totalled $1.24bn.
Janssen Biotech Inc., which licensed the anti-CD38 antibody from Genmab AS of Denmark in 2012, continues to gather evidence aimed at expanding the drug's use still further. In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?